Showing 961-970 of 1350 results for "".
- Novartis: Ligelizumab Receives Breakthrough Therapy Designation in CSUhttps://practicaldermatology.com/news/novartis-ligelizumab-receives-breakthrough-therapy-designation-in-csu/2460656/Ligelizumab from Novartis now has Breakthrough Therapy designation from FDA for the treatment of chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-antihistamine treatment. Ligelizumab
- Skyrizi Performs Well in Phase 3 Studies of PsAhttps://practicaldermatology.com/news/skyrizi-performs-well-in-phase-3-studies-of-psa/2460647/Two Phase 3 studies of Risankizumab (Skyrizi) show improvements in disease activity across joint and skin symptoms in patients with psoriatic arthritis. KEEPsAKE-1 and KEEPsAKE-2 found that significantly more patients treated with risankizumab (150 mg) achieved the primary end
- L'Oréal's SkinCeuticals Taps New GMhttps://practicaldermatology.com/news/loreals-skinceuticals-taps-new-gm/2460621/Stephanie Kramer is L'Oréal's SkinCeuticals new General Manager. Kramer was Global Senior Vice President of Marketing, Product Innovation and Retail at SkinCeuticals. Prior to joining SkinCeuticals in 2019, Kramer served as Vice President of Global Marketi
- More Positive Phase 3 Data for Pfizer's Abrocitinib in ADhttps://practicaldermatology.com/news/more-positive-phase-3-data-for-pfizers-abrocitinib-in-ad/2460607/Positive top-line results from the phase 3 JADE REGIMEN study offer additional data in support of Pfizer's investigational oral once-daily Janus kinase 1 (JAK1) inhibitor for atopic dermatitis (AD). The 52-week study looked at patients 12 and older wi
- In Review: VCS Virtual Format Hailed as a Successhttps://practicaldermatology.com/news/in-review-vcs-virtual-format-hailed-a-success/2460601/After a decade and a half of bringing topline aesthetic education to Las Vegas, VCS went virtual this fall. “While it wasn't live—it was virtual—I knew it was absolutely fantastic,” says meeting
- Two New Studies Suggest Age Is A Primary Determinant Of Melanoma Treatment Resistancehttps://practicaldermatology.com/news/two-new-studies-suggest-age-is-a-primary-determinant-of-melanoma-treatment-resistance/2460595/Age is a primary factor in treatment response in animal and laboratory models of melanoma cells, according to two new studies. The new findings by Johns Hopkins Kimmel Cancer Center and
- FDA Grants Priority Review for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe ADhttps://practicaldermatology.com/news/fda-grants-priority-review-for-pfizers-abrocitinib-an-oral-once-daily-jak1-inhibitor-for-patients-12-and-up-with-moderate-to-severe-ad/2460580/The U.S. Food and Drug Administration (FDA) has granted Priority Review designation to Pfizer’s New Drug Application (NDA) for abrocitinib (100mg and 200mg), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in
- Arcutis: Phase 1/2b Enrollment Complete for ARQ-252 in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-phase-12b-enrollment-complete-for-arq-252-in-chronic-hand-eczema/2460578/Arcutis Biotherapeutics, Inc. has completed enrollment in the Phase 1/2b studyof its Janus kinase type 1(JAK1) ARQ-252 in adult patients with chronic hand eczema. Arcutis has updated its projected topline data from this trial to mid-2021.
- Eczema Missing Link Found: Researchers ID Protein that Triggers AD by Bacteriahttps://practicaldermatology.com/news/eczema-missing-link-found-researchers-id-protein-that-triggers-ad-by-bacteria/2460567/Second immunoglobulin-binding protein (Sbi) is a unique trigger of eczema by Staphylococcus aureus, according to research in the Journal of Allergy and Clinical Immunology. Sbi induces rapid release of Interleukin-33, a key component of the immune response in childhood ecz
- Marketing Exec Lizette Williams Joins RealSelf’s Boardhttps://practicaldermatology.com/news/lizette-williams-global-head-of-vertical-solutions-marketing-at-facebook-joins-realselfs-board/2460540/Marketing and advertising executive Lizette Williams is the newest member of RealSelf’s Board of Directors. Ms. Williams serves as the Global Head of Vertical Solutions Marketing at Facebook. Prior to Facebook she has worked in major marketing roles at McDonald's, Kimberl